159 related articles for article (PubMed ID: 34226123)
1. Virus filter scalability: Demonstration of consistent viral clearance across laboratory and manufacturing scales.
Buesing B; Schwartz A; Shah A; Sohka T; Hirotomi N; Strauss D
Biologicals; 2021 Jul; 72():27-32. PubMed ID: 34226123
[TBL] [Abstract][Full Text] [Related]
2. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
[TBL] [Abstract][Full Text] [Related]
3. Integrity testing of Planova™ BioEX virus removal filters used in the manufacture of biological products.
Sekine S; Komuro M; Sohka T; Sato T
Biologicals; 2015 May; 43(3):186-94. PubMed ID: 25753822
[TBL] [Abstract][Full Text] [Related]
4. Development of small-scale models to understand the impact of continuous downstream bioprocessing on integrated virus filtration.
Lute S; Kozaili J; Johnson S; Kobayashi K; Strauss D
Biotechnol Prog; 2020 May; 36(3):e2962. PubMed ID: 31945257
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the impact of pressure on virus filtration processes and establishing design spaces to ensure effective parvovirus removal.
Strauss D; Goldstein J; Hongo-Hirasaki T; Yokoyama Y; Hirotomi N; Miyabayashi T; Vacante D
Biotechnol Prog; 2017 Sep; 33(5):1294-1302. PubMed ID: 28556575
[TBL] [Abstract][Full Text] [Related]
6. Microscopic visualization of virus removal by dedicated filters used in biopharmaceutical processing: Impact of membrane structure and localization of captured virus particles.
Adan-Kubo J; Tsujikawa M; Takahashi K; Hongo-Hirasaki T; Sakai K
Biotechnol Prog; 2019 Nov; 35(6):e2875. PubMed ID: 31228338
[TBL] [Abstract][Full Text] [Related]
7. Validation and implementation of Planova™ BioEX virus filters in the manufacture of a new liquid intravenous immunoglobulin in China.
Ma S; Pang GL; Shao YJ; Hongo-Hirasaki T; Shang MX; Inouye M; Jian CY; Zhu MZ; Yang HH; Gao JF; Xi ZY; Song DW
Biologicals; 2018 Mar; 52():37-43. PubMed ID: 29434001
[TBL] [Abstract][Full Text] [Related]
8. Integration of Planova filters in manufacturing processes of biologicals improve the virus safety effectively: A review of publicly available data.
Gröner A
Biotechnol Prog; 2024; 40(1):e3398. PubMed ID: 37985214
[TBL] [Abstract][Full Text] [Related]
9. Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies.
Gefroh E; Dehghani H; McClure M; Connell-Crowley L; Vedantham G
PDA J Pharm Sci Technol; 2014; 68(3):297-311. PubMed ID: 25188350
[TBL] [Abstract][Full Text] [Related]
10. Use of bacteriophages as surrogates for mammalian viruses.
McAlister M; Aranha H; Larson R
Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
[TBL] [Abstract][Full Text] [Related]
11. A novel approach to achieving modular retrovirus clearance for a parvovirus filter.
Stuckey J; Strauss D; Venkiteshwaran A; Gao J; Luo W; Quertinmont M; O'Donnell S; Chen D
Biotechnol Prog; 2014; 30(1):79-85. PubMed ID: 24123923
[TBL] [Abstract][Full Text] [Related]
12. New insights into the performance characteristics of the Planova-series hollow-fiber parvovirus filters using confocal and electron microscopy.
Nazem-Bokaee H; Chen D; O'Donnell SM; Zydney AL
Biotechnol Bioeng; 2019 Aug; 116(8):2010-2017. PubMed ID: 30982955
[TBL] [Abstract][Full Text] [Related]
13. Limits in virus filtration capability? Impact of virus quality and spike level on virus removal with xenotropic murine leukemia virus.
Roush DJ; Myrold A; Burnham MS; And JV; Hughes JV
Biotechnol Prog; 2015; 31(1):135-44. PubMed ID: 25395156
[TBL] [Abstract][Full Text] [Related]
14. Meeting report--workshop on virus removal by filtration: trends and new developments.
Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Kreil TR; Robertson JS; Ruffing M; Ruiz S
PDA J Pharm Sci Technol; 2013; 67(2):98-104. PubMed ID: 23569071
[TBL] [Abstract][Full Text] [Related]
15. Impact of virus preparation quality on parvovirus filter performance.
Slocum A; Burnham M; Genest P; Venkiteshwaran A; Chen D; Hughes J
Biotechnol Bioeng; 2013 Jan; 110(1):229-39. PubMed ID: 22766979
[TBL] [Abstract][Full Text] [Related]
16. The removal of phages T1 and PP7, and poliovirus from fluids with hollow-fiber ultrafilters with molecular weight cut-offs of 50,000, 13,000, and 6000.
Oshima KH; Evans-Strickfaden TT; Highsmith AK; Ades EW
Can J Microbiol; 1995; 41(4-5):316-22. PubMed ID: 8590412
[TBL] [Abstract][Full Text] [Related]
17. Filter preconditioning enables representative scaled-down modelling of filter capacity and viral clearance by mitigating the impact of virus spike impurities.
Khan NZ; Parrella JJ; Genest PW; Colman MS
Biotechnol Appl Biochem; 2009 Apr; 52(Pt 4):293-301. PubMed ID: 18844606
[TBL] [Abstract][Full Text] [Related]
18. Choice of parvovirus model for validation studies influences the interpretation of the effectiveness of a virus filtration step.
Nowak T; Popp B; Roth NJ
Biologicals; 2019 Jul; 60():85-92. PubMed ID: 31105022
[TBL] [Abstract][Full Text] [Related]
19. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
20. Impact of proteins and protein fouling on virus retention during virus removal filtration.
Afzal MA; Zydney AL
Biotechnol Bioeng; 2024 Feb; 121(2):710-718. PubMed ID: 37994529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
